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symptoms to be accurately diagnosed, undergoing 4–5 con-
sultations yearly. Additionally, around 25% of these patients 
need to travel to a different region to reach a diagnostic 
facility. The unmet needs of the growing number of patients 
with RDs in general call for special and combined efforts of 
regulatory authorities, health care providers, scientific com-
mittees, practitioners, and patient organisations.
RARE CARDIOVASCULAR DISEASES.  
THE SCOPE OF THE PROBLEM
The population of adults with RDs is widely heterogeneous 
with respect to type and complexity of diseases as well as their 
clinical manifestations, age of onset or natural history. They 
represent a subject of interest of almost all medical fields. 
From all of the RDs registered in the Orphenet database 
a significant number have sole or, more commonly, concomi-
tant cardiovascular manifestation [3]. The accurate number 
of rare cardiovascular diseases (RCD) is, however, difficult to 
assess due to the paucity of designated RCD registries and clas-
sifications, the complexity of these conditions, and their preva-
lence, which in many cases can be as low as 1 < 1,000,000, 
as is the case in Loeys-Dietz syndrome, an aortic aneurysm 
syndrome due to transforming growth factor-beta receptor 
anomalies described in ten families, or in Alström syndrome, 
a multisystemic disorder characterised by dilated cardiomyo-
pathy and cone-rod dystrophy, hearing loss, obesity, insulin 
resistance and hyperinsulinaemia, and progressive hepatic 
and renal dysfunction, which has been identified in about 
450 patients worldwide [5]. Most of the RCDs have a genetic 
background [6]. Some of them are monogenic disorders, like 
Marfan or Brugada syndrome, but many have complex, mul-
tigenic causality. This includes development abnormalities in 
most of the congenital heart diseases or multifactorial origin of 
familial dilated cardiomyopathies. Other RCDs are the result 
of metabolic errors like Fabry disease, an alpha-galactosidase 
DEFINITION AND EPIDEMIOLOGY  
OF RARE DISEASES
Rare diseases (RD) are defined as life-threaten-
ing and chronically debilitating disorders with 
a prevalence of less than 5 per 10,000 of the 
general population [1]. It is estimated that up 
to 8% of European citizens may be affected 
by a RD [2]. Although these numbers seem 
small, they translate to around 27 to 36 mil-
lion people suffering from RDs across Europe. 
According to the Orphanet database (http://
www.orpha.net), a designated reference 
portal for information on rare diseases and 
orphan drugs, there are 6,760 RD entities 
identified to date [3]. 
The definition of RDs, established by 
the European Union (EU) Parliament in 
1999, reflects two fundamental aspects 
related to RDs. First, RDs are of such a low 
prevalence that accumulation of knowl-
edge necessary to develop evidence-based 
management strategies requires multicentre 
networking. Second, due to a lack of ap-
propriate knowledge and awareness about 
RDs in medical communities, these patients 
often hopelessly seek appropriate medical 
attention for extended periods of time, be-
ing continuously misdiagnosed or not diagnosed at all. The 
EurordisCare Survey Programme, investigating RDs patients’ 
experiences and expectations regarding access to diagnosis 
and to health services, showed that as many as 40% of patients 
receive faulty diagnosis initially, which leads to execution of 
inappropriate medical interventions, including surgery, phar-
macotherapy, or psychological treatment [4]. One-quarter 
of these people have to wait 5–30 years from the onset of 
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A deficiency syndrome or Gaucher disease, a glucocerebro-
sidase deficiency syndrome, autoimmune abnormalities like 
systemic vasculitis or connective tissue diseases affecting the 
heart, infectious like Lyme carditis or HIV-induced pulmonary 
arterial hypertension or neoplastic including primary or second-
ary cardiac tumours, as well as cardiovascular complications 
of non-cardiac tumours like secondary hypertension in the 
course of pheochromocytoma. This implies that the diversity 
of RCDs should not only be understood by the vast number of 
the diseases per se. The presence of rare combinations of more 
common conditions in one patient or uncommon phenotypes 
of cardiovascular disorders not necessarily of low prevalence 
also define the heterogeneity of RCDs and drive the need for 
attentive mulidisciplinarity in attending these patients. 
The lack of disease specific therapy for most of the RCDs 
represents a substantial drawback in managing this group of 
patients. To date there are only a few medicinal products 
registered in the European Medicinal Agency for the treatment 
of orphan cardiovascular diseases [7]. These include a group 
of pulmonary arterial hypertension-specific drugs and enzyme 
replacement agents used to treat metabolic syndromes like 
Fabry disease, Hunter syndrome, Pompe or Gaucher disease, 
or mucopolysaccharidosis. Additionally, a number of RCDs 
may require an interventional approach, with development 
and improvement may required engaging efforts of highly 
specialised centres of various fields. 
RARE DISEASES: EU PRIORITY ACTION 
Recognising the significant disproportion in the access to 
high-quality healthcare, between patients with rare and com-
mon diseases, the EU authorities developed legislative acts 
such as Commission Communication Rare Diseases: Europe’s 
Challenge (2008) [2] and Council Recommendation on an 
Action in the Field of Rare Diseases (2009) [8], in which they 
identified RDs as a priority for EU public health. Strategies 
presented in these texts concentrate on three main fields: 
(1) Improving Recognition and Visibility on Rare Diseases, 
(2) Supporting Policies on Rare Diseases in the Member 
States, (3) Developing European cooperation, coordination, 
and regulation for rare diseases. In order to apply these 
measures systematically, a coherent pan-European strategy 
was launched: the European Project for Rare Diseases Na-
tional Plans Development (EUROPLAN). All countries have 
been advised to undertake efforts to elaborate public health 
plans aimed at the improvement of the quality of care for this 
population by implementing Council recommendations [9]. 
Following these guidelines, the Polish Ministry of Health has in-
stituted a group of experts in the field of RDs, who elaborated 
the National Plan for RDs [10]. The plan concentrates on the 
formulation of classification and registries of RDs in Poland, 
creation of the reference centres networks, improvement in 
the access to highly specialised, integrated health care, and 
development of research and education in this field. 
RECOGNITION OF RARE DISEASES
Raising awareness is the principal instrument to encourage 
recognition and tackle negligence of the issue of RDs [11]. Cer-
tain action points have been adopted into European legislation 
for this purpose. These include promotion of the universal 
RD definition, development of applicable codification and 
classification(s) systems, induction of research, and dissemi-
nation of accurate knowledge and information in a format 
adapted to the needs of professionals and patients. For these 
purposes an official reference portal has been established: 
the Orphanet. 
EUROPEAN CENTRES OF EXPERTISE
In the field of RDs, where the expertise is scattered through-
out Europe, designation of Centres of Expertise (CoE) or 
Centres of Reference is of particular importance. It has been 
underscored that no patient should feel neglected because 
he or she cannot have an access to a well-known, highly 
specialised centre composed of qualified individuals located 
nearby. For this reason, from 2004 onward, the Commission 
of High-Level Group on Health Services and Medical Care 
supported by the Rare Diseases Task Force Group began to 
elaborate on the concept of CoE [12]. This Working Group on 
European Centres of Reference ascertained that the idea of 
CoE is of highly positive value, which will provide benefit to 
patients and health professionals. A CoE for a RD or a group 
of RDs would bring together a panel of multidisciplinary 
competences, organised in a structured manner in order to 
accumulate expertise and maximise limited resources. The 
identification of a CoE varies, however, across Europe [13]. 
Some countries have expert clinics specialised by a disease or 
a group of diseases, and others have centres dedicated to the 
management of the majority of RDs in general. Some national 
centres are uniquely focused on the clinical management 
of patients, whilst others undertake clinical research only. 
This heterogeneity reflects the differences of national health 
care systems. It also represents the diversity of this group of 
diseases and the variability in the expertise and interests of 
involved physicians, experts, or researchers, and, for most, 
the breadth of the patients’ needs and expectations. Being 
aware of this diversity on one hand, but recognising the need 
for unified definition of the concept of CoE on the other, the 
aforementioned Working Group followed by the labours 
of the European Union Committee of Experts on Rare Dis-
eases (EUCERD) proposed a versatile model for establishing 
European CoE, reflecting their mission, form, and scope of 
activities, criteria for designation and evaluation, and their 
European dimension [14, 15]. CoE should therefore be able 
to provide high-quality healthcare services based on good 
practice guidelines, collaborate with legal authorities to es-
tablish public health strategies, cooperate with industry and 
patients’ organisations, reinforce medical training and research 
to produce and disseminate evidence based knowledge, and 
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be ready to form international co-operations. Adopting these 
recommendations in selecting CoEs at the national level is 
aimed at facilitating their recognition within patients’ commu-
nities and local professionals, in order to improve the referral 
and diagnostic process. Another issue that these regulations 
highlight is the multi-disciplinary approach that the CoEs 
should demonstrate. The complexity and diversity of many 
RDs implies the need for integration of medical, paramedical, 
psychological, and social resources to provide service that 
cannot be delivered elsewhere with the same quality. 
To date there are around 56 CoEs focused on various 
types of RDs registered in Poland, of which at least three are 
identified as designated CoEs according to the Orphanet da-
tabase (Table 1). The Centre for Rare Cardiovascular Diseases 
(CRCD) in the John Paul II Hospital in Krakow is regarded as 
a designated CoE for the diagnosis and treatment of RCDs 
[16]. The mission of the Centre is to (1) provide efficient 
diagnostic and therapeutic opportunities for RCD patients; 
(2) develop national and international collaboration net-
works; (3) disseminate knowledge, targeting both physicians 
and patients; (4) promote research and development; and 
(5) organise psychological and social support to patients and 
families (Table 2).  
EUROPEAN REFERENCE NETWORKS 
Given the specific nature of the matter of RDs, it becomes 
obvious however, that establishing CoEs with the highest 
expected expertise for each RD or group of RDs in each 
European country is an unrealistic concept. Therefore, creat-
ing networks of CoEs at the pan-European level appears to 
be the key element to achieve overall progress in this area 
[17]. As for the principle of the Cross-border Healthcare 
Directive, patients who cannot receive sufficient attention 
in their local health care facilities should have an opportu-
nity to seek more adequate care in other CoEs hosted by 
other European Member States. But having to attend a clinic 
located in a foreign country can induce negative logistic, 
financial, or psychological outcomes for patients with often 
very debilitating rare conditions. The creation of the European 
Reference Networks (ERN) would, for this matter, ensure that 
the expertise would be the one that travels rather than the 
patients themselves. The current approach to the concept of 
ERNs is presented in the Recommendations on Rare Disease 
European Reference Networks document formulated by the 
EUCERD in 2013 [18]. Major potential benefits of ERNs are 
seen in (1) improving patient’s access to multidisciplinary 
teams of experts by rearranging their referral pathways initi-
ated by primary care physicians; (2) creating platforms for 
sharing knowledge and expertise, organising trainings for 
health professionals, and exchanging laboratory samples, 
radiological images, or diagnostic procedures; (3) establish-
ing registries, databases, and biobanks to increase cohorts for 
research studies and clinical trials; and (4) bringing together 
patients and patient organisation networks to promote their 
impact in the field. 
The CRCD in Krakow represents a node of the orphan 
cardiovascular diseases ERN [16]. It actively cooperates with 
a broad panel of national and international experts of various 
disciplines of medicine and health sciences (Table 2). The 
Centre has additionally elaborated referral pathways within 
district hospitals in the Malopolska region to improve access 
to medical advice for RCD patients and their physicians. 
RESEARCH AND DEVELOPMENT
Amplifying research and development activities in the field 
of RDs requires specific initiatives to attract interest from 
researchers and industry. Academic research faces consider-
able disadvantages including lack of necessary collaborative 
efforts, fewer funding opportunities, the need for an alterna-
tive design for clinical trials, and a limited number of patients, 
which implies less interest for initiating clinical studies. For 
industry at the same time, RDs represent a small, niche mar-
ket, which translates into expected low societal impact, and 
thus low profit. Nevertheless, the need to extend knowledge 
about epidemiology, pathophysiology or natural history of 
RDs and developing preventive, diagnostic and therapeutic 
interventions is unquestionable. This issue has been recog-
nised by the Council Recommendations and is supported by 
several global initiatives. At the local and transnational level, 
research on RDs is being addressed as one of the priority ar-
eas in the health field under the EU Framework Programmes 
for Research and Technological Development (FP), which 
together with E-RARE the ERA-Net for Research Programmes 
on Rare Diseases and The International Rare Disease Research 
Consortium provide funding for over 4,690 ongoing research 
projects on about 2,177 different RDs [19]. Many of these 
programmes are recognised as disease registries. There are 
around 600 disease registries running in Europe according to 
the Orphanet database [20]. 
The CRCD in Krakow, in addition to serving as a platform 
for the exchange of expertise is intentionally engaged in the 
propagation of knowledge and research development in the 
field of RCDs (Table 2). A number of scientific initiatives are 
continuously being conducted in the Centre [21–27]. These 
include RCD registries that originate from a large database 
of patients with a variety of rare and non-rare cardiovascu-
lar diseases referred to the departments of the John Paul II 
Hospital in Krakow. 
An issue requesting separate attention in the European 
legislation is the development and marketing of drugs to treat, 
prevent or diagnose rare conditions. Although the European 
Regulation on Orphan Medicinal Products has established 
a centralised procedure for designation of these products and 
has put in place incentives for the research, marketing and 
development, access to these medicines is often difficult and 
unequal from country to country [28]. According to analysis 
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Table 1. List of Expert Centres in Poland identified by Orphanet*
Institution
Cystic fibrosis clinic Bialystok (Medical University)
Rare inflammatory bowel disease Torun (The Nicolaus Copernicus Medical University)
Primary immunodeficiency clinic Torun (The Nicolaus Copernicus Medical University)
Primary immunodeficiency clinic Gdansk (Medical University Clinical Centre)
Rare systemic or rheumatologic disease clinic Krakow (Jagiellonian University Medical College)
Hereditary Angioedema ClinicRD Krakow (Clinical and Environmental Allergology, Jagiellonian University Medical College)
Primary immunodeficiency clinic Krakow (Polish-American Institute of Paediatrics, Jagiellonian University Medical College)
Rare diabetes mellitus and Gaucher disease Krakow (Polish-American Institute of Paediatrics, Jagiellonian University Medical College)
Centre for Rare Cardiovascular DiseasesRD Krakow (John Paul II Hospital, Jagiellonian University Medical College)
Cystic fibrosis and rare respiratory diseases Rabka-Zdroj (National Institute for Tuberculosis and Lung Diseases)
Primary immunodeficiency clinic Lodz (Medical University)
Rare pancreas and liver disease clinic Lublin (Medical University)
Rare paediatric cancers and haematological disorders Lublin (Medical University)
Primary immunodeficiency clinic Poznan (Medical University)
Congenital heart malformations clinic Poznan (Medical University)
Cystic fibrosis clinic Poznan (Medical University)
Rare digestive disease clinic Szczecin (Pomeranian Medical University)
Cystic fibrosis clinic Karpacz (Pulmonology and Allergology Centre)
Lymphoma and myeloid haemopathy oncologic clinic Warsaw (Institute of Haematology and Transfusiology)
Disorders of Haemostasis and Internal Medicine Warsaw (Institute of Haematology and Transfusiology)
General and Haematological Surgery Clinic Warsaw (Institute of Haematology and Transfusiology)
Cystic fibrosis clinic Warsaw (Institute of Mother and Child)
Clinic for rare pulmonary disease Warsaw (Institute for Tuberculosis and Pulmonary Diseases)
Porphyria clinic Warsaw (Institute of Haematology and Transfusiology)
Wilson Disease ClinicRD Warsaw (Institute of Psychiatry and Neurology)
Paediatric rheumatologic clinic Warsaw (Institute of Rheumatology)
Rare breast cancer clinic Warsaw (Maria Sklodowska-Curie Memorial Cancer, Centre and Institute of Oncology)
Colorectal cancer clinic Warsaw (Maria Sklodowska-Curie Memorial Cancer, Centre and Institute of Oncology)
Rare gastrointestinal tumour clinic Warsaw (Maria Sklodowska-Curie Memorial Cancer, Centre and Institute of Oncology)
Gynaecological oncology clinic Warsaw (Maria Sklodowska-Curie Memorial Cancer, Centre and Institute of Oncology)
Rare lung cancer clinic Warsaw (Maria Sklodowska-Curie Memorial Cancer, Centre and Institute of Oncology)
Lymphoma clinic Warsaw (Maria Sklodowska-Curie Memorial Cancer, Centre and Institute of Oncology)
Neuro-oncology clinic Warsaw (Maria Sklodowska-Curie Memorial Cancer, Centre and Institute of Oncology)
Sarcoma clinic Warsaw (Maria Sklodowska-Curie Memorial Cancer, Centre and Institute of Oncology)
Urogenital cancer clinic Warsaw (Maria Sklodowska-Curie Memorial Cancer, Centre and Institute of Oncology)
Paediatric haematology clinic Warsaw (Paediatric Hospital)
Paediatric pneumology and allergology Warsaw (Paediatric Hospital)
Reference centre for metabolic diseases Warsaw (The Children’s Memorial Health Institute)
Clinic for rare nephrology diseases Warsaw (The Children’s Memorial Health Institute)
Clinic for rare hepatobiliary diseases Warsaw (The Children’s Memorial Health Institute)
Cystic fibrosis clinic Warsaw (The Children’s Memorial Health Institute)
Gastrology and hepatology clinic Warsaw (The Children’s Memorial Health Institute)
Clinic for immunologic diseases Warsaw (The Children’s Memorial Health Institute)
Clinic for rare surgical pediatric cardiac diseases Warsaw (The Children’s Memorial Health Institute)
Clinic for rare surgical neurology diseases Warsaw (The Children’s Memorial Health Institute)
Clinic for rare neurology diseases Warsaw (The Children’s Memorial Health Institute)
Clinic for rare ophthalmology diseases Warsaw (The Children’s Memorial Health Institute)
Clinic for oncologic diseases Warsaw (The Children’s Memorial Health Institute)
Clinic for rare urology diseases Warsaw (The Children’s Memorial Health Institute)
Congenital malformation surgical clinic Warsaw (Medical University)
Hirschprung disease clinic Warsaw (Medical University)
Rare neurologic disease clinic Warsaw (Medical University)
Epidemolysis Bullosa Clinic Warsaw (Medical University)
Primary immunodeficiency clinic Wroclaw (Provincial Hospital)
RD — designated centres of expertise; *www.orpha.net
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carried out by Orphanet there are about 144 medicinal 
products authorised by the European market to potentially 
treat 120 diseases [29]. Development of novel therapeutics 
and elaboration of standards for clinical trials adequate to 
limited cohorts of patients is essential to achieve progress in 
this area [30]. 
CLASSIFICATION OF RARE  
CARDIOVASCULAR DISEASES
The lack of appropriate inventory of RDs remain an obstacle in 
promoting their recognition. Of the thousands of known RDs 
only about 250 have a distinct code in the existing 10th version 
of the International Classification of Diseases (ICD). As a result, 
development of public health measures including prevalence, 
Table 2. Activities of the Centre for Rare Cardiovascular Diseases (CRCD) in Krakow
I. CRCD, the centre of reference 
 — Provides highly specialised, integrated health care for RCD patients
 — Provides state-of-the-art diagnostic and therapeutic opportunities for RCD patients
 — Has access to genetic diagnostics and orphan drugs
 — Serves as a consultation centre for local and international physicians
 — Organises video/tele-consultation meetings 
II. CRCD, the node of the European Reference Network
 — Cooperates with experts such as: adult and paediatric cardiologists and cardiac surgeons, electrocardiologists, pulmonologists,  
anaesthesiologists, thoracic surgeons, neurologists, gynaecologists and obstetricians, nephrologists, haematologists, immunologists, 
diabetes specialists and endocrinologists, psychologists and psychiatrists, basic scientists
 — Established a network of collaboration with European Expert Centres including: Deutsches Herzzentrum in Berlin, San Raffaele  
Hospital in Milan, Univeristy of Hull, Lithuanian University of Health Sciences in Kaunas, Pauls Stradins Clinical University Hospital in Riga, 
Academic Hospital IRCCS Foundation Policlinico San Matteo in Pavia, Henri Mondore Clinic Universitaire Vasculaire in Paris, Department of 
Paediatric Cardiology and Congenital Heart Defects at the German Heart Centre in Munich, Pulmonary Hypertension Centre at the Univer-
sity of Bologna, Royal Infirmary Hospital of Edinburgh, Medical University of Vienna, Department of Cardiology at the Philipps University 
of Marburg, Inherited Cardiac Disease Clinic in the Heart Hospital in London
 — Formed internet-based referral links with regional and national medical departments (www.chorobyrzadkie.szpitaljp2.krakow.pl/)
III. CRCD, the knowledge and expertise disseminating institution
 — Organises symposia on RCDs during European Society of Cardiology Congresses
 — Organised 1st International Conference on Rare Cardiovascular Diseases in 2012 in Krakow
 — Coordinate workshops on RCDs for regulatory authorities, health care providers, scientific committees, practitioners and patient  
organisations
 — Runs a website (www.crcd.eu)
 — Established a “Journal of Rare Cardiovascular Diseases” (www.jrcd.eu)
IV. CRCD, the research institution
 — Conducts registries for RCDs
 — Formulated classification of RCDs [31]
 — Holds observational and interventional studies on RCDs
V. CRCD, the educational institution
 — Provides training opportunities on RCDs
 — Encourages international internship placements in European expert centres
 — Elaborated multidisciplinary educational curriculum on RCDs for medical students at the Jagiellonian University Medical College
 — Published text on RCDs “Rare Cardiovascular Diseases: From Classification to Clinical Examples”
RCD — rare cardiovascular disease
incidence, mortality, and morbidity is imposed. Disorders that 
are not visible to the health information systems consequently 
lack allocation of funds and resources. This creates a vicious 
cycle, which maintains the state of inequality. A few attempts 
is being undertaken to classify RDs. The Orphanet classification 
system, which is currently being developed, or the 11th version 
of the ICD that is being revised by the World Health Organisa-
tion. Independently of the abovementioned projects the CRCD 
in Krakow has proposed an exhaustive classification of RCDs 
in order to support formulation of a common language in this 
field [31]. The RCD Classification derives from the experience 
of the Centre and a profound review of the majority of pub-
lications available through PubMed. It is aimed at facilitating 
recognition of RCDs and grouping the expertise in the main 
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fields of RCDs. It provides a systemic inventory of RCDs based 
on the intensity of clinical symptoms and major pathological 
mechanisms. The main classes of the Classification include 
rare diseases of systemic circulation (Class I), rare diseases 
of pulmonary circulation (Class II), rare diseases of the heart 
(cardiomyopathies) (Class III), rare congenital cardiovascular 
diseases (Class IV), rare arrhythmias (Class V), cardiac tumours 
and cardiovascular diseases in malignancy (Class VI), cardio-
vascular diseases in pregnancy (Class VII), and unclassified rare 
cardiovascular diseases (Class VIII) (Table 3). They are further 
subdivided into groups and subgroups as appropriate. Each 
entity or group of entities is assigned unique RCD Classification 
code. An attempt has also been made to refer to the existing 
10th version of the ICD system by allocating its code; however, 
it was often not possible due to its evident limitations in terms 
of RCDs. The formulation of the RCD Classification was a chal-
lenging initiative and therefore it is currently undergoing an 
intensive review by international forum of experts.
CONCLUSIONS
RDs including RCDs are becoming a significant burden for 
patients, physicians and health care systems worldwide. RD 
patients often face overwhelming inequities in access to the 
professional care, which they would expect. Certain actions 
have been adopted at the European legislation level in order to 
overcome these barriers; however, a number of issues remain 
unresolved. Creation of the CoEs and ERNs concentrated 
on a particular RD or group of RDs, ignition of research and 
development, and facilitating the recognition are the key 
points in achieving progress in this field. The CRCD in the John 
Paul II Hospital in Krakow is an intentionally designed institu-
tion aimied at improving the care for RCDs patients. Being 
the national CoE and a part of the ERN, it serves as a forum 
Table 3. Classification of Rare Cardiovascular Diseases
Main Class Group Subgroup Example RCD code ICD10 
I — Rare diseases of systemic circulation A…O 1…0 a…o I-(A).(1).(a) ...
II — Rare diseases of pulmonary circulation A…O 1…0 a…o II-(A).(1).(a) …
III — Rare diseases of the heart (cardiomyopathies) A…O 1…0 a…o III-(A).(1).(a) …
IV — Rare congenital cardiovascular diseases A…O 1…0 a…o IV-(A).(1).(a) …
V — Rare arrhythmias A…O 1…0 a…o V-(A).(1).(a) …
VI — Cardiac tumours and cardiovascular diseases in malignancy A…O 1…0 a…o VI-(A).(1).(a) …
VII — Cardiovascular diseases in pregnancy A…O 1…0 a…o VII-(I)-(A).(1).(a) …
VIII — Unclassified rare cardiovascular diseases A…O 1…0 a…o VIII-(1) …
Main classes of the classification accommodate the intensity of clinical symptoms and the underlining pathology. They are subdivided into groups 
and subgroups representing pathophysiological and symptomatological context. An appropriate example specifies the clinical setting. Each entity 
or group of entities is assigned a unique RCD code, which derives from the previously mentioned divisions. Example: I-1A.1 indicates a patient 
with anomaly of the circle of Willis, an entity included in class I of the RCD classification: I (class): rare diseases of the systemic circulation,  
1 (group): anatomical malformations of the arteries, A (subgroup): cerebral arteries, 2 (example): anomalies of the circle of Willis.  
An attempt has also been made to refer to the existing 10th version of the ICD system.  
RCD — rare cardiovascular diseases; O — other
for the exchange of knowledge and expertise supporting 
research and education in the field of orphan cardiovascular 
diseases. Its role in promoting awareness of RCDs has gained 
recognition among members of the national and international 
community of cardiologists after arranging symposia during the 
world’s largest cardiology meetings, the European Society of 
Cardiology (ESC) Congresses in Paris (2011), Munich (2012), 
Amsterdam (2013), and Barcelona (2014) [32]. 
The RCD Classification, the “Journal of Rare Cardiovas-
cular Diseases”, the CRCD website, and the textbook Rare 
Cardiovascular Diseases: From Classification to Clinical Ex-
amples published by the Centre are tools in our commitment 
to establishing a routine dialogue among those who manage 
and care for patients who have so far been labelled as “no 
one’s” or “orphan”, a dialogue that include patient-specific 
discussions aimed at patient-specific solutions. 
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